

<2.0 kg
OR
<35 weeks gestational age at birth

Birth to < 4 weeks of age
OR < 3 kg

AZT + 3TC + NVP

≥ 4 weeks of age
AND
≥ 3 kg

ABC + 3TC + DTG

Baseline Assessment

- Clinical review
- Bloods: confirmatory HIV PCR (or HIV VL), CD4 count, FBC +/- HIV drug resistance test if mother failing treatment on TLD2 or a protease inhibitor regimen
- Counsel parent / caregiver
- Ensure the mother is on ART, and advise that breastfeeding is recommended for all infants living with HIV

Review after 1 week then 1-2 weekly

- Clinical review and counselling
- Check baseline blood results
- If indeterminate / negative confirmatory HIV PCR test result, refer to Guideline for Family-Centered Transmission Prevention of Communicable Infections
- Monitor weight gain and adjust ARV doses

Review when ≥4 weeks of age

- Clinical review and counselling
- If <3 kg, continue AZT + 3TC + NVP
- If >3 kg, switch to ABC + 3TC + DTG (refer to ARV dosing chart for doses)
- Continue monitoring and evaluations as per ***"Monitoring on ART"***

Gestational age at birth	Chronological age	Zidovudine (AZT)	Lamivudine (3TC)	Nevirapine (NVP)
		Solution 10 mg/mL	Solution 10 mg/mL	Solution 10 mg/mL
< 30 weeks	Birth - < 4 weeks	2 mg/kg/dose twice daily	2 mg/kg/dose twice daily	2 mg/kg/dose twice daily
	≥ 4 weeks - < 8 weeks	3 mg/kg/dose twice daily	4 mg/kg/dose twice daily	4 mg/kg/dose twice daily
	≥ 8 weeks - < 10 weeks	12 mg/kg/dose twice daily		6 mg/kg/dose twice daily
≥ 30 - < 35 weeks	Birth - < 2 weeks	2 mg/kg/dose twice daily	2 mg/kg/dose twice daily	2 mg/kg/dose twice daily
	≥ 2 - < 4 weeks	3 mg/kg/dose twice daily		4 mg/kg/dose twice daily
	≥ 4 - < 6 weeks		4 mg/kg/dose twice daily	6 mg/kg/dose twice daily
	≥ 6 - < 8 weeks	12 mg/kg/dose twice daily		

When weight is ≥2 kg and ≥35 weeks corrected gestational age, review ARVs and refer to table ***"ART for the Term Neonate"***